AI-generated summary
In this pilot randomized, sham-controlled trial of 20 adults with mild cognitive impairment, the authors report that home-based near-infrared light therapy was safe, feasible and well tolerated. Compared with sham, active treatment was associated with greater gains in global cognition and episodic memory, along with metabolic and network-level changes. Because the trial was small and pilot in design, the authors call for larger, double-blind, multicenter studies.
- Participants
- 20
- Who or what was studied
- Adults aged 50 years or older with mild cognitive impairment
- Wavelengths
- 810 nm
- Limits stated in the abstract
- The trial was a small, single-blind pilot with 20 participants, so its findings are preliminary and need confirmation in larger double-blind studies.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Transcranial photobiomodulation, Mild cognitive impairment, Photobiomodulation, Sham, Randomized controlled trial, Near-infrared, Mitochondria. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.